LACI‐2.

Study name	LACunar Intervention (LACI‐2) Trial‐2: assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease
Methods	Phase 2b preparatory to phase 3 randomised, partial factorial, open‐label, blinded endpoint trial
Participants	400
Interventions	Isosorbide mononitrate oral titrated dosing  Cilostazol oral titrated dosing  Isosorbide mononitrate + cilostazol
Outcomes	Dose‐specific trial medication tolerability (over 36 months) Incidence of treatment emergent adverse effects (safety) over 36 months Treatment efficacy: rate of individual participant events (stroke, TIA, myocardial ischaemia, cognitive impairment and dementia) over 36 months
Starting date	2018
Contact information	Chief Investigator: Joanna M Wardlaw, University of Edinburgh, UK
Notes